fbpx Johnson & Johnson Innovation Names Awardees in the Immunology Innovations QuickFire Challenge: Precision Medicine in Immune-Mediated Disease - News | JLABS

Johnson & Johnson Innovation Names Awardees in the Immunology Innovations QuickFire Challenge: Precision Medicine in Immune-Mediated Disease

April 29, 2022 -
18 days ago
Other news

April 29, 2022 — As we recognize International Day of Immunology, Johnson & Johnson Innovation, together with Janssen Research & Development, announce that Enhanc3D Genomics, Metadvice, Flexomics and ImYoo Inc. are the awardees of the Immunology Innovations QuickFire Challenge: Precision Medicine in Immune-Mediated Disease. The challenge invited innovators with potential solutions aiming to advance precision medicine approaches in immune-mediated disease to apply.

Enhanc3D Genomics (EG) is developing a functional genomics technology focused on the uncharted non-coding regions of the human genome with the aim to identify genetic interactions that are disease-associated and can be targeted for therapeutic and biomarker applications.

Metadvice is combining the latest clinical guidelines, augmented with insights from AI-based analyses of past decisions, to help improve the quality, consistency and personalization of clinical decision making.

Flexomics is developing the next generation of high-throughput screening platform capable of simultaneous functional and genomic analysis of hundreds of thousands of individual cells and cell-to-cells interactions to guide the development of immune-based therapeutics.

ImYoo Inc. aims to enhance precision medicine by coupling at-home small-volume blood self-collection and single-cell resolution gene expression to help provide incredibly rich data with minimal logistical burden. By giving people the ability to get such samples on their own whenever they need to, ImYoo Inc. aims to engage with individuals continuously and sample a wide array of immune states, as well as make longitudinal and high-frequency sampling studies easier to achieve.

To help advance their science, the awardees are receiving a combination of rewards, including grant funding from a total of $500,000 and/or one year of residency at an available JLABS with the use of a bench, workstation and access to the global Johnson & Johnson Innovation – JLABS network. All awardees will receive mentorship from experts across the Johnson & Johnson Family of Companies.*

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest healthcare challenges.

* Subject to the execution of the necessary agreements and documentation

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About Janssen Research & Development LLC

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.


Related content